Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References and Readings
Bari, M., Shiwach, R., Jimenez, R., Siegert, S., & O’Brien, C. (2016). Open-label extension of KINECT: A phase 2 study of Valbenazine (NBI-98854) for Tardive Dyskinesia (S27. 001). Neurology, 86(16 Supplement), S27–001.
Drug Interaction Effects. http://www.drugs.com/drug_interactions.html
Drug Molecule Images. http://www.worldofmolecules.com/drugs/
Free Drug Online and PDA Software. www.epocrates.com
Free Drug Online and PDA Software. www.medscape.com
General Information. www.medscape.com
Hauser, R. A., Factor, S. A., Marder, S. R., Knesevich, M. A., Ramirez, P. M., Jimenez, R., …, O’Brien, C. F. (2017). KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. American Journal of Psychiatry, 174(5), 476–484.
Physicians’ desk reference (71st ed.) (2017). Montvale: Thomson PDR.
Pill Identification. http://www.drugs.com/pill_identification.html
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this entry
Cite this entry
Gonzalez, E.A. (2018). Valbenazine. In: Kreutzer, J.S., DeLuca, J., Caplan, B. (eds) Encyclopedia of Clinical Neuropsychology. Springer, Cham. https://doi.org/10.1007/978-3-319-57111-9_9268
Download citation
DOI: https://doi.org/10.1007/978-3-319-57111-9_9268
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-57110-2
Online ISBN: 978-3-319-57111-9
eBook Packages: Behavioral Science and PsychologyReference Module Humanities and Social SciencesReference Module Business, Economics and Social Sciences